Advertisement

May 19, 2020

Guerbet’s Vectorio Kit Approved in Canada for Interventional Oncology Procedures

May 19, 2020—Guerbet announced the registration in Canada of Vectorio, a kit for imaging of hepatocellular carcinoma (HCC) that provides a set of Lipiodol (Guerbet)-resistant medical devices, including patented syringes, stopcock, and sampling devices.

According to the company, Vectorio is dedicated to Lipiodol ultra fluid injection for imaging of liver tumors in adults with known HCC during interventional oncology procedures. It has been validated for resistance to Lipiodol for up to 24 hours.

Vectorio was designed and manufactured in France by Medex, a Guerbet group company. Vectorio is registered in Canada and Germany for imaging of HCC. Additionally, it received CE Mark approval in 2017 and is available in 25 European countries where conventional transarterial chemoembolization procedures are approved for Lipiodol ultra fluid.

Advertisement


May 20, 2020

Relation of SARS2-CoV-2 and Stroke Evaluated in Patients in a New York Health Care System

May 19, 2020

Mentice Launches VIST G7 Endovascular Simulation Platform